Table 1.
Patient characteristics.
| Identification set |
Validation set |
|||||||
|---|---|---|---|---|---|---|---|---|
| BOS (N = 40) |
BOS (N = 12) |
|||||||
| STA (N = 49) | DIAG (N = 26) | PRED (N = 32) | STA (N = 13) | DIAG (N = 8) | PRED (N = 11) | |||
| Mean age at Tx (range) | 40.2 (16–62) | 40.6 (15–65) | 43.3 (15–65) | ns | 38.8 (23–62) | 50.8 (29–63) | 49.5 (27–63) | ns |
| Sex | ns | ns | ||||||
| M (%) | 25 (51) | 14 (53.8) | 17 (53.1) | 7 (53.8) | 6 (75) | 8 (72.7) | ||
| F (%) | 24 (49) | 12 (46.2) | 15 (46.9) | 6 (46.2) | 2 (25) | 3 (27.3) | ||
| BMI | 20 | 20.5 | 21.2 | ns | 18.7 | 22.9 | 21.2 | ns |
| Pathology leading to Tx | ns | ns | ||||||
| Emphysema/COPD, n (%) | 11 (22.4) | 8 (30.8) | 9 (28.2) | 3 (23) | 3 (37.5) | 5 (45.4) | ||
| CF, n (%) | 29 (59.2) | 9 (30.6) | 10 (31.3) | 9 (69.2) | 2 (25) | 4 (36.4) | ||
| PAH, n (%) | 3 (6.1) | 2 (7.7) | 2 (6.3) | – | – | – | ||
| IPF, n (%) | 1 (2) | 2 (7.7) | 4 (12.5) | 1 (7.8) | 2 (25) | 1 (9.1) | ||
| Other, n (%) | 5 (10.2) | 5 (19.2) | 7 (21.9) | – | 1 (12.5) | 1 (9.1) | ||
| Type of Tx | ns | ns | ||||||
| Double lung, n (%) | 41 (82.5) | 19 (73.1) | 24 (75) | 11 (84.6) | 7 (87.5) | 10 (90.9) | ||
| Single lung, n (%) | 5 (12.5) | 6 (23.1) | 7 (21.9) | 2 (15.4) | – | – | ||
| Heart lung, n (%) | 2 (2.5) | 1 (3.8) | – | – | 1 (12.5) | 1 (9.1) | ||
| Lobar, n (%) | 1 (2.5) | – | 1 (3.1) | – | – | – | ||
| Induction | ns | ns | ||||||
| Basiliximab, n (%) | 17 (34.7) | 5 (19.2) | 9 (28.1) | 3 (23.1) | 1 (12.5) | 2 (18.2) | ||
| Thymoglobulin, n (%) | 17 (34.7) | 12 (46.2) | 16 (50) | 7 (53.8) | 1 (12.5) | 2 (18.2) | ||
| None, n (%) | 15 (30.6) | 9 (34.6) | 7 (21.9) | 3 (23.1) | 6 (75) | 7 (63.6) | ||
| Immunosuppressives | ||||||||
| Steroids, n (%) | 49 (100) | 26 (100) | 32 (100) | 13 (100) | 8 (100) | 11 (100) | ||
| Tacrolimus, n (%) | 38 (79.6) | 18 (69.2) | 23 (71.9) | 11 (84.6) | 3 (37.5) | 6 (54.5) | ||
| Cyclosporin, n (%) | 11 (22.4) | 8 (30.8) | 9 (28.1) | 2 (15.4) | 5 (62.5) | 5 (45.4) | ||
| MMF/MPA, n (%) | 47 (95.9) | 26 (100) | 29 (90.1) | 13 (100) | 7 (87.5) | 10 (90.1) | ||
| Azithromycin | 11 (22.4) | 20 (76.9)† | 12 (37.5) | p < 0.0001 | 6 (46.2) | 7 (87.5) | 6 (54.5) | |
| Acute cellular rejections | ns | ns | ||||||
| Ever A1 grade, n (%) | 12 (24.5) | 7 (26.9) | 2 (6.25) | 4 (30.7) | 5 (62.5) | 2 (18.2) | ||
| Ever ≥A2 grade, n (%) | 4 (8.2) | 4 (15.4) | 2 (6.25) | 1 (7.7) | 1 (12.5) | 1 (9.1) | ||
| Infectionsa | ns | |||||||
| Bacteria, n (%) | 39 (79.6) | 23 (88.5) | 28 (87.5) | 11 (84.6) | 6 (75) | 8 (72.7) | ||
| Fungi, n (%) | 28 (57.2) | 21 (80.8) | 21 (65.6) | 6 (46.2) | 4 (50) | 7 (63.6) | ||
| Virus, n (%) | 19 (38.8) | 16 (61.5) | 14 (43.8) | 3 (23) | 4 (50) | 3 (27.3) | ||
| Collection time post-Tx (days ± SD)b | 6 mo: 196 ± 31 | 642 ± 254# | 210 ± 70## | p < 0.0001 | 6 mo: 185 ± 12 | 738 ± 86# | 311 ± 39## | p < 0.0001 |
| 12 mo: 375 ± 28 | 12 mo: 364 ± 9 | |||||||
| FEV1 (% predicted) at collectionb | 6 mo: 74.5 ± 19.5 | 50.7 ± 15.5† | 72.5 ± 19.9 | p < 0.0001 | 6 mo: 74.7 ± 17.1 | 57.7 ± 18.9†† | 83.4 ± 14.6 | 0.032 |
| 12 mo: 80.6 ± 19.2 | 12 mo: 81.5 ± 18.4 | |||||||
| Smoking status | ns | ns | ||||||
| Non smoker | 30 | 12 | 17 | 9 | 3 | 5 | ||
| Weaned | 19 | 14 | 13 | 4 | 5 | 6 | ||
| Active smoker | 0 | 0 | 2 | 0 | 0 | 0 | ||
Clinical parameters of the patients included in the identification and validation sets. The p values were calculated with the Fisher’s exact test for categorical variables and Kruskal–Wallis test with Dunn’s ad hoc pairwise comparisons for continuous variables.
aNumber of patients with at least one event of infection during the follow-up.
bAt 6 months and 12 months posttransplantation.
#p < 0.05 in DIAG vs. STA 6 mo and PRED.
##p < 0.05 in PRED vs. STA 12 mo.
†p < 0.0001 in DIAG vs. PRED and vs. STA.
††p < 005 in DIAG vs. STA 12 mo.